Clinical Trials
34 trialsNCT06137144 2026-05-19
PRIMAVERA
AstraZeneca
Phase 1/2 Recruiting
NCT06254495 2026-05-08
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Terminated
NCT06870487 2026-05-08
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Phase 1 Terminated
NCT07195916 2026-05-04
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Phase 1 Recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT02732275 2026-04-28
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT07192471 2026-04-20
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Not yet recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05403450 2026-02-23
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Taiho Oncology, Inc.
Phase 1 Active not recruiting
NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
NCT06485219 2026-02-06
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Active not recruiting
NCT04390737 2026-01-30
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06909877 2026-01-30
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT07180771 2026-01-28
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
Boryung Pharmaceutical Co., Ltd
Phase 2 Not yet recruiting
NCT06120504 2026-01-26
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Terminated
NCT02264613 2026-01-13
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Aileron Therapeutics, Inc.
Phase 1/2 Completed
NCT06776952 2026-01-09
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc.
Phase 3 Recruiting
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT06511895 2025-12-24
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Dizal Pharmaceuticals
Phase 2 Completed
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04703192 2025-12-09
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo
Phase 2 Active not recruiting
NCT07234162 2025-11-18
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06072131 2025-10-23
CRESCENDO
Acrotech Biopharma Inc.
Phase 3 Recruiting
NCT06733441 2025-10-10
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
Phase 1 Recruiting
NCT04234048 2025-09-22
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Phase 1 Recruiting
NCT06947967 2025-09-15
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT04018248 2025-09-10
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
Phase 1 Completed
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT06385522 2025-07-08
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Boston Immune Technologies and Therapeutics
Phase 1 Not yet recruiting
NCT06511869 2025-07-04
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Dizal Pharmaceuticals
Phase 2 Completed